Your browser doesn't support javascript.
loading
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.
Oplustil O'Connor, Lenka; Rulten, Stuart L; Cranston, Aaron N; Odedra, Rajesh; Brown, Henry; Jaspers, Janneke E; Jones, Louise; Knights, Charlotte; Evers, Bastiaan; Ting, Attilla; Bradbury, Robert H; Pajic, Marina; Rottenberg, Sven; Jonkers, Jos; Rudge, David; Martin, Niall M B; Caldecott, Keith W; Lau, Alan; O'Connor, Mark J.
Afiliación
  • Oplustil O'Connor L; AstraZeneca, Alderley Park, Macclesfield, United Kingdom.
  • Rulten SL; Genome Damage and Stability Centre, University of Sussex, Falmer, Brighton, United Kingdom.
  • Cranston AN; KuDOS Pharmaceuticals Ltd, Cambridge, United Kingdom.
  • Odedra R; AstraZeneca, Alderley Park, Macclesfield, United Kingdom.
  • Brown H; AstraZeneca, Alderley Park, Macclesfield, United Kingdom.
  • Jaspers JE; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Jones L; KuDOS Pharmaceuticals Ltd, Cambridge, United Kingdom.
  • Knights C; KuDOS Pharmaceuticals Ltd, Cambridge, United Kingdom.
  • Evers B; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Ting A; AstraZeneca, Alderley Park, Macclesfield, United Kingdom.
  • Bradbury RH; AstraZeneca, Alderley Park, Macclesfield, United Kingdom.
  • Pajic M; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Rottenberg S; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Jonkers J; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Rudge D; AstraZeneca, Alderley Park, Macclesfield, United Kingdom.
  • Martin NM; KuDOS Pharmaceuticals Ltd, Cambridge, United Kingdom.
  • Caldecott KW; Genome Damage and Stability Centre, University of Sussex, Falmer, Brighton, United Kingdom.
  • Lau A; AstraZeneca, Alderley Park, Macclesfield, United Kingdom.
  • O'Connor MJ; AstraZeneca, Alderley Park, Macclesfield, United Kingdom. mark.j.oconnor@astrazeneca.com.
Cancer Res ; 76(20): 6084-6094, 2016 10 15.
Article en En | MEDLINE | ID: mdl-27550455
Asunto(s)
Buscar en Google
Imprimir
XML
PubMed Links

Bases de datos: MEDLINE Asunto principal: Ftalazinas / Piperidinas / Poli(ADP-Ribosa) Polimerasas / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Neoplasias Experimentales Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cancer Res Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido
Buscar en Google
Imprimir
XML
PubMed Links

Bases de datos: MEDLINE Asunto principal: Ftalazinas / Piperidinas / Poli(ADP-Ribosa) Polimerasas / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Neoplasias Experimentales Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cancer Res Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido